• Active, not recruiting

NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM

Updated: May 23

NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma


e-prism-elotuzumab

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma


Sponsor

Dana-Farber Cancer Institute


Collaborators

Bristol-Myers Squibb

Celgene

Blood Cancer Research Partnership

Multiple Myeloma Research Consortium

The Leukemia and Lymphoma Society


Multiple Locations


This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

 

ClinicalTrials.gov Identifier: NCT02279394


Official Title: E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

First Posted : October 31, 2014


Click here for details on ClinicalTrials.gov

 

Elotuzumab : National Cancer Institute

Elotuzumab : MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Drug: Elotuzumab

Drug: Lenalidomide

Drug: Dexamethasone

 

Locations

United States, Colorado

United States, Connecticut

United States, Illinois

United States, Maine

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, North Carolina



Posts Archive